论文部分内容阅读
目的:分析美多巴联合普拉克索治疗帕金森病的有效性及安全性,为帕金森病的临床治疗提供更多依据。方法:选取2014年1月至2016年8月广东医科大学附属医院门诊及住院所收治的38例帕金森病患者,随机分为对照组和观察组,各19例,对照组以美多巴治疗,观察组在对照的基础上加之普拉克索治疗,观察分析两组患者的治疗效果。结果:观察组治疗总有效率为100%,对照组患者的治疗总有效率73.68%,观察组治疗总有效率明显高于对照组,且无严重的不良反应出现,差异具有统计学意义(P<0.05)。结论:美多巴联合普拉克索治疗帕金森病具有较为突出的效果,能够显著的帮助病患改善症状,且无严重的不良反应发生安全性较高。
OBJECTIVE: To analyze the efficacy and safety of metoparamin combined with pramipexole in the treatment of Parkinson’s disease and provide more evidences for the clinical treatment of Parkinson’s disease. Methods: From January 2014 to August 2016, 38 patients with Parkinson’s disease admitted to the outpatient department and hospitalization of Affiliated Hospital of Guangdong Medical University were randomly divided into control group and observation group, 19 cases in each group. The control group was treated with methyldopa . The observation group was treated with pramipexole on the basis of the control and the therapeutic effects of the two groups were observed and analyzed. Results: The total effective rate was 100% in the observation group and 73.68% in the control group. The total effective rate in the observation group was significantly higher than that in the control group, and no serious adverse reactions were found (P <0.05). Conclusion: The combined treatment of Parkinson’s disease with metoparavole and pramipexole has a remarkable effect, which can significantly help patients to improve their symptoms and has no serious adverse reactions and safety.